Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status:
Completed
Trial end date:
2019-11-15
Target enrollment:
Participant gender:
Summary
This Phase I/II placebo controlled trial will evaluate tofacitinib in subjects with diffuse
cutaneous systemic scleroderma (dcSSc). This trial is intended to provide safety, and
tolerability data in participants with dcSSc when dosed to target exposures similar to that
used in adult participants with rheumatoid arthritis.